Pacira BioSciences
PCRX
156 hedge funds and large institutions have $1.37B invested in Pacira BioSciences in 2018 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 57 increasing their positions, 54 reducing their positions, and 29 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 2 → 4 (+2)
6% more repeat investments, than reductions
Existing positions increased: 57 | Existing positions reduced: 54
1% more capital invested
Capital invested by funds: $1.36B → $1.37B (+$9.8M)
2.13% less ownership
Funds ownership: 107.43% → 105.3% (-2.1%)
7% less funds holding
Funds holding: 168 → 156 (-12)
38% less first-time investments, than exits
New positions opened: 18 | Existing positions closed: 29
56% less call options, than puts
Call options by funds: $12.2M | Put options by funds: $27.6M
Top Buyers
| 1 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$48.5M |
| 2 |
CCM
Consonance Capital Management
New York
|
+$38.6M |
| 3 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
+$26.5M |
| 4 |
HM
HealthCor Management
New York
|
+$19.2M |
| 5 |
ECP
Elk Creek Partners
Denver,
Colorado
|
+$12.7M |
Top Sellers
| 1 |
Westfield Capital Management
Boston,
Massachusetts
|
-$26M |
| 2 |
AC
Armistice Capital
New York
|
-$22.6M |
| 3 |
EIP
Epoch Investment Partners
New York
|
-$21.9M |
| 4 |
Alyeska Investment Group
Chicago,
Illinois
|
-$20.2M |
| 5 |
Jennison Associates
New York
|
-$16M |
PCRX Hedge Fund Activity: Q2 2018 in Review
156 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Pacira BioSciences (PCRX) for Q2 2018, worth a combined $1.37B — up 0.72% from $1.36B a quarter earlier.
Sellers outnumbered buyers: 29 funds closed out of PCRX and 18 opened new positions — a net loss of 11 holders — while 54 trimmed existing stakes and 57 added.
The largest buyer was PFM Health Sciences, adding an estimated $48.5M. The largest seller was Westfield Capital Management, exiting entirely with an estimated $26M sold.
- 156 institutional investors held Pacira BioSciences (PCRX) as of Q2 2018, down from 168 in Q1 2018.
- Funds reported $1.37B of Pacira BioSciences stock for Q2 2018, up 0.72% quarter-over-quarter.
- 18 funds opened new Pacira BioSciences positions in Q2 2018 and 29 closed out, a net change of -11 holders.
- The largest Pacira BioSciences buyer in Q2 2018 was PFM Health Sciences, an estimated $48.5M added.
- The largest Pacira BioSciences seller in Q2 2018 was Westfield Capital Management, an estimated $26M sold.
Based on aggregated 13F filings for Q2 2018.